In the first half of the 20th century, antiepileptic drugs were introduced and gained the attention of epilepsy patients around the world. To this day, antiepileptic drugs remain the best choice for people with epilepsy, but recently, the FDA (U.S. Food and Drug Administration) warned medical professionals that patients treated with antiepileptic drugs may develop suicidal ideation and suicidal behavior. The conclusion was based on an analysis of placebo-controlled studies involving 11 antiepileptic drugs for epilepsy, psychiatric disorders and other conditions. This analysis showed that the incidence of suicidal ideation and suicidal behavior was approximately twice as high in patients treated with antiepileptic drugs as in the placebo group (0. 43% vs. 0. 22%). The U.S. FDA included commonly used antiepileptic drugs in the analysis study. The antiepileptic drugs included in the analysis were: carbamazepine (trade names Carbatrol, Equetro, Tegretol, and Tegretol XR), felbamate (trade name Felbatol), gabapentin (trade name Neurontin ), lamotrigine (trade name Lamictal), levetiracetam (trade name Keppra), oxcarbazepine (trade name Trileptal), pregabalin (trade name Lyrica), tiagabine (trade name Gabitril), topiramate (trade name Topafunction) valproate (trade names Depakote, Depakote ER, Depakote ER, Depakote ER, Depakote ER, Depakote ER, Depakote ER, Depakote ER, Depakote ER, Depakote ER. Depakote ER, Depakene and Depacon) and zonisamide (trade name Zonegren). An increase in suicidal ideation and suicidal behavior was observed in patients within 1 week of starting antiepileptic therapy, and this risk persisted during the 24-week study period. The FDA noted that although only the 11 drugs listed above were analyzed, all antiepileptic drugs may have a risk of increasing suicidal thoughts and attempts in patients as well as varying degrees of response due to patient dose, body composition, and duration of drug use, and that labeling of such drugs will be generally modified. Dose-related adverse reactions, such as sedation with phenobarbital, dizziness, diplopia, and ataxia with carbamazepine and phenytoin sodium, can be reduced by slowly increasing the dose from a small dose, not exceeding the maximum therapeutic dose recommended in the instructions. Almost all conventional antiepileptic drugs have been reported with idiosyncratic adverse reactions, mainly skin damage, severe hepatotoxicity, hematologic damage, and lamotrigine and oxcarbazepine among the newer antiepileptic drugs have also been reported. They are generally mild and resolve rapidly after discontinuation, with some severe cases being discontinued immediately and treated aggressively symptomatically. Long-term adverse reactions are related to cumulative doses. If the patient is given the smallest dose that can control seizures for a number of years without seizure section consider gradual withdrawal or reduction of the drug to help reduce long-term adverse reactions to antiepileptic drugs. The incidence of malformations in the offspring of women with epilepsy is about twice that of normal women. The causes of malformations in the offspring are multiple, including genetic factors, seizures, and the use of antiepileptic drugs. The FDA says that although 70-80% of epileptic patients can achieve more satisfactory results with antiepileptic drug treatment, it still does not rule out the tendency for antiepileptic drugs to stimulate suicide in patients, and antiepileptic drugs should be taken with caution.